1,2-diethoxy-3-ethyl-benzene | 131358-05-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1,2-diethoxy-3-ethyl-benzene
• 英文别名: 1,2-Diaethoxy-3-aethyl-benzol；1,2-Diethoxy-3-ethylbenzene
• CAS: 131358-05-9
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: FAZOHODJTTYSEH-UHFFFAOYSA-N

物化性质

• 沸点：
  254.0±20.0 °C(Predicted)
• 密度：
  0.955±0.06 g/cm3(Predicted)
• 保留指数：
  1384

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2-diethoxy-3-ethyl-benzene 、 氢碘酸 生成 2-羟基-3-甲氧基甲苯
  参考文献：
  名称：

  Hirschel, Monatshefte fur Chemie, 1902, vol. 23, p. 188

  摘要：

  DOI：
• 作为产物：
  描述：

  溴乙烷 、 邻苯三酚 在 氢氧化钾 作用下， 生成 1,2-diethoxy-3-ethyl-benzene
  参考文献：
  名称：

  Hirschel, Monatshefte fur Chemie, 1902, vol. 23, p. 188

  摘要：

  DOI：

文献信息

• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EZH2 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016073956A1

  公开（公告）日：2016-05-12

  The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors.

  本公开提供了任一式（I）和（II）中的化合物。本文描述的化合物是组蛋白甲基转移酶抑制剂（例如增强子齿同源蛋白1（EZH1）和增强子齿同源蛋白2（EZH2）），可用于治疗和/或预防广泛范围的疾病（例如增生性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。本公开还提供了识别EZH1和/或EZH2抑制剂的方法。
• Diazepane derivatives and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10308653B2

  公开（公告）日：2019-06-04

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

  本公开提供了式（I）化合物及其药用组合物。已发现式（I）化合物可结合溴基链和/或含溴基链的蛋白质（如溴外末端（BET）蛋白质）。还提供了这些化合物和药物组合物的方法、用途和试剂盒，用于抑制溴基团和/或含溴基团蛋白的活性（如活性增加），治疗和/或预防受试者与溴基团或含溴基团蛋白相关的疾病（如增殖性疾病、心血管疾病、病毒感染、纤维化疾病、神经系统疾病、代谢性疾病、内分泌疾病和辐射中毒）。这些化合物、药物组合物和试剂盒还可用于男性避孕。
• EZH2 inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US11236082B2

  公开（公告）日：2022-02-01

  The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.

  本公开提供了式(I)和(II)中任一项的化合物。本文所述化合物是组蛋白甲基转移酶（如泽斯特同源增强子 1 (EZH1)和泽斯特同源增强子 2 (EZH2)）的抑制剂，可用于治疗和/或预防多种疾病（如增殖性疾病）。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。本公开还提供了鉴定EZH1和/或EZH2抑制剂的方法。
• HAZAI, ISTVAN;LEDNICZKY, LASZLO, J. CHROMATOGR., 520,(1990) C. 149-155
  作者：HAZAI, ISTVAN、LEDNICZKY, LASZLO

  DOI：——

  日期：——
• PROCESS FOR PRODUCING PROPYLENE BLOCK COPOLYMER
  申请人：FUJIWARA Yasuki

  公开号：US20100004395A1

  公开（公告）日：2010-01-07

  A production process of a propylene block copolymer, comprising the step (I) of polymerizing propylene alone or a combination of propylene with an olefin other than propylene, in the presence of a defined polymerization catalyst, to form a polymer component (1), and the step (II) of copolymerizing propylene with an olefin other than propylene in the presence of the polymer component (1), to form a polymer component (2), wherein a combination of a transition metal compound such as Zr(OR 1 ) 4 and Hf(OR 1 ) 4 (R 1 being a hydrocarbon group) with an ether group-containing linear hydrocarbon compound and/or a Lewis base compound is added to the above polymerization system between the ending point of the step (I) and the starting point of the step (II), or during the step (II).

表征谱图